128 related articles for article (PubMed ID: 19779050)
1. The role of CBFbeta in AML1-ETO's activity.
Park S; Speck NA; Bushweller JH
Blood; 2009 Sep; 114(13):2849-50. PubMed ID: 19779050
[No Abstract] [Full Text] [Related]
2. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
3. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
[TBL] [Abstract][Full Text] [Related]
4. The role of CBFbeta in AML1-ETO's activity.
Kwok C; Zeisig BB; Dong S; So CW
Blood; 2010 Apr; 115(15):3176-7. PubMed ID: 20395424
[No Abstract] [Full Text] [Related]
5. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH
Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331
[TBL] [Abstract][Full Text] [Related]
6. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
7. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
Wichmann C; Grez M; Lausen J
Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.
Liu Y; Chen W; Gaudet J; Cheney MD; Roudaia L; Cierpicki T; Klet RC; Hartman K; Laue TM; Speck NA; Bushweller JH
Cancer Cell; 2007 Jun; 11(6):483-97. PubMed ID: 17560331
[TBL] [Abstract][Full Text] [Related]
10. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
[TBL] [Abstract][Full Text] [Related]
11. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
12. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain.
Plevin MJ; Zhang J; Guo C; Roeder RG; Ikura M
Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10242-10247. PubMed ID: 16803958
[TBL] [Abstract][Full Text] [Related]
13. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera.
Huang G; Shigesada K; Wee HJ; Liu PP; Osato M; Ito Y
Blood; 2004 Apr; 103(8):3200-7. PubMed ID: 15070703
[TBL] [Abstract][Full Text] [Related]
15. Are kinases factors in core binding factor leukemia?
Andolina JR; Corey SJ
Leuk Lymphoma; 2009 Sep; 50(9):1397-8. PubMed ID: 19672779
[No Abstract] [Full Text] [Related]
16. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
[No Abstract] [Full Text] [Related]
17. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes.
Kwok C; Zeisig BB; Qiu J; Dong S; So CW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2853-8. PubMed ID: 19202074
[TBL] [Abstract][Full Text] [Related]
18. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.
Goyama S; Schibler J; Cunningham L; Zhang Y; Rao Y; Nishimoto N; Nakagawa M; Olsson A; Wunderlich M; Link KA; Mizukawa B; Grimes HL; Kurokawa M; Liu PP; Huang G; Mulloy JC
J Clin Invest; 2013 Sep; 123(9):3876-88. PubMed ID: 23979164
[TBL] [Abstract][Full Text] [Related]
19. AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia.
Downing JR
Leukemia; 2001 Apr; 15(4):664-5. PubMed ID: 11368373
[No Abstract] [Full Text] [Related]
20. Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.
Roh SH; Kasembeli M; Galaz-Montoya JG; Trnka M; Lau WC; Burlingame A; Chiu W; Tweardy DJ
J Biol Chem; 2016 Feb; 291(9):4732-41. PubMed ID: 26706127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
